Compounded GLP-1 medication in South Africa: what you need to know
If you have been looking at GLP-1 medication for weight loss in South Africa, you have almost certainly come across compounded versions. They are cheaper, widely available, and until recently, easy to access through clinics, compounding pharmacies, and online platforms. For many South Africans priced out of branded products, they looked like the practical option.
The regulatory picture changed significantly between May and June 2026. SAHPRA raided the country's largest compounding operation, ordered a product recall, and on 22 June 2026 the Pretoria High Court ordered that operation to stop immediately. This article explains what compounding is, what the risks are, what the court ruling means, and why Loome uses registered branded medication only.
What compounding is, and what it is not
Compounding is a legitimate and long-standing pharmacy practice. A compounding pharmacist prepares a customised medicine for an individual patient when a commercially available product does not meet their specific needs: a different dose, a different formulation, the removal of an allergen. It is individual, prescription-based, and strictly regulated.
What compounding is not, under South African law, is large-scale manufacturing of medicines for general commercial distribution. The Medicines Act is clear: compounded medicines may only be prepared for a specific patient on the basis of a valid prescription. A compounding pharmacy producing tens of thousands of doses a month for general sale is not compounding in the legal sense. It is manufacturing, without the regulatory scrutiny that manufacturing requires.
This distinction is at the heart of what SAHPRA found in South Africa's GLP-1 compounding market.
What SAHPRA found
On 11 May 2026, SAHPRA and the South African Pharmacy Council conducted a joint inspection at iDexis (Pty) Ltd, trading as Sentra Pharmacy in Silverton, Pretoria. The inspection findings, published in SAHPRA's media release on 23 May 2026, described what the regulator called critical regulatory non-compliance.1
Specifically, SAHPRA found illegal importation of active pharmaceutical ingredients, no analytical testing to confirm identity, potency, or purity, inadequate sterile manufacturing conditions, and a high risk of contamination. The court later heard that iDexis had been producing around 84,500 doses of semaglutide per month, more than Novo Nordisk's combined South African sales of Ozempic and Wegovy. At those volumes, this was not compounding for individual patients. It was industrial-scale production of an unregistered medicine.
SAHPRA seized all GLP-1 products on the premises and instructed iDexis to initiate a full recall of products already distributed.
The court ruling
On 22 June 2026, the Pretoria High Court granted Novo Nordisk an interim interdict ordering iDexis to immediately cease the manufacture, supply, and marketing of its compounded semaglutide products. Judge Van Niekerk found that iDexis had been using an unregistered, chemically synthesised version of semaglutide from an undisclosed source. The order remains in force pending the outcome of further regulatory investigations.
The specific safety risks of compounded GLP-1s
The iDexis case is the most visible SA example, but the safety concerns around compounded GLP-1 products are not unique to one company. They are structural to how these products are made and distributed.
Unverified active ingredients
SAHPRA has stated that compounded products claiming to contain semaglutide have not undergone verification to confirm the active pharmaceutical ingredient is identical to the registered product.2 The court in the iDexis case heard that the compound used a chemically synthesised form of semaglutide, whereas Novo Nordisk's registered product is biologically derived. These are not the same molecule. The chemically synthesised version has not been evaluated by SAHPRA for safety or effectiveness.
Salt forms of semaglutide used by some compounders, such as semaglutide acetate and semaglutide sodium, are different active ingredients from the registered product. Their use in compounded medicines is illegal under section 14(4) of the Medicines Act.
Dosing errors
Branded GLP-1 products like Ozempic and Wegovy come in pre-filled injection pens with fixed, clearly labelled doses. Compounded semaglutide typically comes in multidose vials that require the patient to draw up and measure their own dose using a syringe. This is a documented source of serious error.
The FDA issued a safety alert in July 2024 after receiving reports of patients administering five to twenty times the intended dose of compounded semaglutide, due to confusion between milligrams, millilitres, and units.3 A case series published in a poison control centre journal documented patients self-administering ten-fold dosing errors, experiencing severe nausea, vomiting, and abdominal pain lasting days.4 By end of 2024, the FDA's adverse event reporting system had logged over 900 adverse events linked to compounded semaglutide and tirzepatide globally, including 17 deaths.5
Contamination risk
GLP-1 medications are injectable sterile medicines. Sterile manufacturing requires controlled conditions that are far more demanding than standard pharmacy compounding. SAHPRA's inspection at iDexis specifically flagged inadequate sterile manufacturing conditions and a high contamination risk. An SA doctor speaking to the media described treating a patient who developed large areas of inflamed skin after using a compounded injectable product: "That immediately tells me it's a contaminated product."
Unknown additives
Compounded products may contain additives not present in the registered product, including B12, citric acid variants, or other components added for preservation or palatability. These have not been evaluated for safety in combination with semaglutide or tirzepatide.
Why we use registered branded medication only
Loome prescribes Wegovy and Mounjaro, the SAHPRA-registered branded products. Not because they are more expensive, but because of what registration actually means for a patient.
A SAHPRA-registered medicine has been through a full pre-market review: the active ingredient is confirmed, the dose is verified, the manufacturing conditions are inspected, and the product has been evaluated for safety and effectiveness in the population it is indicated for. That process is what Judge Van Niekerk referred to when he noted that Novo Nordisk had "subjected itself to a process of stringent screening and testing of its products by SAHPRA in the public interest and in compliance with its duty to obey the law."
When a clinician prescribes a registered product, they know what they are prescribing. The dose in the pen is the dose on the label. The active ingredient is the one studied in the clinical trials. The sterility has been confirmed. None of those things can be assumed for a compounded product, even one prescribed in good faith.
The price difference between compounded and branded products is real, and we do not dismiss it. Access is a genuine problem in South Africa. But the clinical position is clear: the risks of an unverified, unstandardised injectable are not risks that can be managed around. They are structural to the product.
What the ruling means for people currently using compounded products
If you are currently using compounded semaglutide or tirzepatide, three things are worth knowing.
First, do not stop abruptly without speaking to a clinician. Stopping GLP-1 medication suddenly can result in rapid return of appetite and weight regain. If your supply has been disrupted by the iDexis recall or the court order, the right move is to speak to the doctor or clinician who prescribed the medication and discuss switching to a registered product or managing the transition.
Second, if you have experienced any adverse reactions, report them to SAHPRA. The reporting form is available at sahpra.org.za. Reports from patients are part of how the regulator builds its safety picture.
Third, registered alternatives are currently available. Wegovy (semaglutide up to 2.4 mg weekly) is registered by SAHPRA for weight management and is available at licensed SA pharmacies. Mounjaro (tirzepatide) received SAHPRA weight management approval in October 2025 and is available via Aspen Pharmacare. Pricing has come down: Wegovy's starting dose sits around R1,873 per month as of mid-2026 following Novo Nordisk's price reductions earlier this year. For full pricing detail, see our article How much does GLP-1 weight-loss treatment cost in South Africa?
Common questions
Is compounded semaglutide legal in South Africa?
Compounding for an individual patient on a valid prescription, using a registered active ingredient, is legal. What is not legal is large-scale manufacture and commercial distribution of compounded GLP-1 products. The Pretoria High Court confirmed this on 22 June 2026, ruling that iDexis had been compounding illegally.
Is compounded semaglutide safe?
SAHPRA cannot confirm that compounded products contain the correct active ingredient at the correct dose, or that they have been manufactured in sterile conditions. The evidence from SA inspections and international adverse event data suggests the risks are real and not theoretical. Dosing errors, contamination, and unknown additives are documented harms, not hypothetical ones.
What is the difference between compounded and branded semaglutide?
Branded semaglutide (Ozempic, Wegovy) is biologically derived, SAHPRA-verified, and comes in a pre-filled pen with a fixed dose. The iDexis compounded version used a chemically synthesised form from an undisclosed source, in a multidose vial requiring self-measurement. The court found these are not equivalent products.
What should I do if I am currently using compounded semaglutide or tirzepatide?
Speak to a registered healthcare provider before stopping or changing anything. If you want to continue GLP-1 treatment on a registered product, Wegovy and Mounjaro are both available through licensed SA pharmacies on prescription.
References
- SAHPRA and SAPC (2026) 'Joint media release: enforcement action against unlawful manufacturing and distribution of unregistered GLP-1 medicines', 23 May 2026. Available at: sahpra.org.za.
- SAHPRA (2024) 'SAHPRA's position on GLP-1 and GIP-GLP-1 products that are compounded, substandard and falsified', December 2024. Available at: sahpra.org.za.
- US Food and Drug Administration (2024) 'FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products', 26 July 2024. Available at: fda.gov.
- Chastain, D.B., et al. (2023) 'Administration errors of compounded semaglutide reported to a poison control centre: case series', Journal of the American Pharmacists Association, 63(6), pp. 1723-1727.
- National Academy of Medicine (2025) 'Compounded drugs threaten patient safety', 1 August 2025. Available at: nam.org.
- Novo Nordisk South Africa (2026) 'High Court rules in favour of Novo Nordisk South Africa, halting illicit compounding with immediate effect', 23 June 2026. Available at: golegal.co.za.